Trial Profile
An Open-label Comparison of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2020
Price :
$35
*
At a glance
- Drugs Latanoprost (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Peregrine Ophthalmic
- 20 Apr 2016 Status changed from active, no longer recruiting to completed.
- 23 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.